https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42678 Wed 31 Aug 2022 16:53:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55180 Wed 24 Apr 2024 09:33:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30657 Wed 17 Nov 2021 16:30:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8348 Sat 24 Mar 2018 08:39:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7468 Sat 24 Mar 2018 08:38:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26423 Sat 24 Mar 2018 07:27:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34772 Mon 23 Sep 2019 11:18:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47386 Mon 16 Jan 2023 15:24:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41856 18 years with lower GI hemorrhage requiring hospital admission from November 2011 to January 2014 were screened for trial eligibility (N = 265). INTERVENTIONS: A total of 100 patients were recruited after exclusions and were randomly assigned 1:1 to either tranexamic acid or placebo. MAIN OUTCOME MEASURES: The primary outcome was blood loss as determined by reduction in hemoglobin levels. The secondary outcomes were transfusion rates, transfusion volume, intervention rates for bleeding, length of hospital stay, readmission, and complication rates. RESULTS: There was no difference between groups with respect to hemoglobin drop (11 g/L of tranexamic acid vs 13 g/L of placebo; p = 0.9445). There was no difference with respect to transfusion rates (14/49 tranexamic acid vs 16/47 placebo; p = 0.661), mean transfusion volume (1.27 vs 1.93 units; p = 0.355), intervention rates (7/49 vs 13/47; p = 0.134), length of hospital stay (4.67 vs 4.74 d; p = 0.934), readmission, or complication rates. No complications occurred as a direct result of tranexamic acid use. LIMITATIONS: A larger multicenter trial may be required to determine whether there are more subtle advantages with tranexamic acid use in some of the secondary outcomes. CONCLUSIONS: Tranexamic acid does not appear to decrease blood loss or improve clinical outcomes in patients presenting with lower GI hemorrhage in the context of this trial. see Video Abstract at https://links.lww.com/DCR/A453.]]> Fri 12 Aug 2022 17:04:19 AEST ]]>